Boston Scientific Corp. (BSX) has announced that it has obtained approval from the U.S. Food and Drug Administration (FDA) for its navigation-enabled FARAWAVE NAV Ablation Catheter, designed for the treatment of paroxysmal atrial fibrillation (AF). Additionally, the company has secured FDA 510(k) clearance for its FARAVIEW Software. These innovations are set to enhance visualization during cardiac ablation procedures when used in conjunction with the FARAPULSE Pulsed Field Ablation (PFA) System.
Boston Scientific emphasized that these cutting-edge technologies are exclusively compatible with its current cardiac mapping technology, alongside its latest product, the OPAL HDx Mapping System. The company plans to commence the U.S. launch of both the FARAWAVE NAV Ablation Catheter and the FARAVIEW Software immediately.
This development is the latest addition to the Boston Scientific PFA portfolio. The FARAVIEW Software utilizes magnetic tracking for the FARAWAVE NAV Ablation Catheter, enabling physicians to monitor the site of pulsed field applications and visualize cumulative therapy delivery to strategically guide ablation procedures.
Furthermore, the PFA delivery via the FARAWAVE NAV Ablation Catheter is trackable through automated tagging technology. This feature is designed to aid physicians in planning, executing, and verifying therapy applications by indicating approximate pulsed field locations within the heart, based on the catheter's position, according to the company.
